Search for content, post, videos

Q&A: Renée Aguiar-Lucander, CEO, Calliditas Therapeutics

Renée Aguiar-Lucander Photo Jann Lipka
Calliditas Therapeutics is about to bring its treatment for IgA nephropathy to the market – addressing a significant unmet medical need. Calliditas, formed in 2004, is a Swedish clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in o
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.